Nephrol Dial Transplant (2001) 16: 36-40
© 2001 European Renal Association-European Dialysis and Transplant Association
The role of inflammation in the anaemia of end-stage renal disease
Huddinge University Hospital, Stockholm, Sweden
Abstract
Chronic inflammation is a common feature of end-stage renal disease (ESRD) that is gaining increasing attention as a major cause of morbidity and mortality. It is well established that ESRD per se carries a heightened risk of inflammatory disorders and other co-morbid conditions, but it should also be pointed out that dialysis treatment per se can bring additional risk factors for inflammation, such as impure dialysate or bio-incompatible membranes. Inflammation has recently been associated with atherosclerosis and malnutrition in ESRD, and this link has led to the development of the malnutrition, inflammation, atherosclerosis (MIA) hypothesis. This describes a syndrome whereby raised levels of pro-inflammatory cytokines (such as IL-1, IL-6 and TNF-
) are a common link between malnutrition, inflammation and atherosclerosis. Also, anaemia appears to be an important element linking elevated cytokine levels with poor patient outcomes. Several mechanisms for cytokine-induced anaemia have been proposed, including intestinal bleeding, impaired iron metabolism and suppression of bone marrow erythropoiesis and erythropoietin production. These effects suggest that pro-inflammatory cytokines may also be an important cause of lack of response to recombinant human erythropoietin (rh-Epo) therapy. In the light of this putative role of pro-inflammatory cytokines, anti-cytokine agents may prove useful to optimize efficacy of rh-Epo in anaemic chronic renal failure patients. Other potential therapeutic strategies include minimizing exposure to causes of inflammation from various co-morbid conditions, such as persistent infections and chronic heart failure.
Keywords: anaemia; cytokines; dialysis; epoetin; erythropoietin; inflammation
Notes
Correspondence and offprint requests to: Dr Peter Stenvinkel, Associate Professor, Department of Renal Medicine K56, Huddinge University Hospital, 141 86 Stockholm, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Chonchol, G. Lippi, M. Montagnana, M. Muggeo, and G. Targher Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2879 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Weiss and L. T. Goodnough Anemia of Chronic Disease N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Korevaar, J. G. van Manen, F. W. Dekker, D. R. de Waart, E. W. Boeschoten, R. T. Krediet, and for the NECOSAD Study Group Effect of an Increase in C-Reactive Protein Level during a Hemodialysis Session on Mortality J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2916 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cooper, A. Mikhail, M. W. Lethbridge, D. M. Kemeny, and I. C. Macdougall Pentoxifylline Improves Hemoglobin Levels in Patients with Erythropoietin-resistant Anemia in Renal Failure J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1877 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Cooper, A. Mikhail, M. W. Lethbridge, D. M. Kemeny, and I. C. Macdougall Increased Expression of Erythropoiesis Inhibiting Cytokines (IFN-{gamma}, TNF-{alpha}, IL-10, and IL-13) by T Cells in Patients Exhibiting a Poor Response to Erythropoietin Therapy J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1776 - 1784. [Abstract] [Full Text] [PDF]
|
|